New targeted therapy shrinks advanced gastrointestinal tumours for 65% of patients in an early study
A new, targeted cancer therapy for advanced gastrointestinal stromal tumours (GIST) has shown promising early results, with 65 per cent of patients who received velzatinib as first-line treatment experiencing tumour […]
2026 ASCO Annual Meeting
The 2026 ASCO Annual Meeting is more than an event—it’s your chance to Be Part of Something Bigger, connect with global colleagues, and immerse yourself in groundbreaking research and innovation. […]
Combining two targeted therapies improves response rate in paediatric low-grade gliomas
A new study found that combining the targeted therapies, dabrafenib and trametinib, considerably improved the overall response rate (ORR) in paediatric patients with BRAF V600 mutation-positive low-grade gliomas. The ORR […]
